BR112018005175A2 - predição de resposta clínica a antagonistas de il23 usando biomarcadores de via de il23 - Google Patents

predição de resposta clínica a antagonistas de il23 usando biomarcadores de via de il23

Info

Publication number
BR112018005175A2
BR112018005175A2 BR112018005175A BR112018005175A BR112018005175A2 BR 112018005175 A2 BR112018005175 A2 BR 112018005175A2 BR 112018005175 A BR112018005175 A BR 112018005175A BR 112018005175 A BR112018005175 A BR 112018005175A BR 112018005175 A2 BR112018005175 A2 BR 112018005175A2
Authority
BR
Brazil
Prior art keywords
antagonists
prediction
clinical response
pathway biomarkers
biomarkers
Prior art date
Application number
BR112018005175A
Other languages
English (en)
Portuguese (pt)
Inventor
Higgs Brandon
Morehouse Chris
Vainshtein Inna
Li Jing
Chen Jingjing
Streicher Katie
Ranade Koustubh
Liang Meina
Faggioni Raffaella
A Gasser Robert Jr
W Georgantas Robert Iii
Rees William
Lee Yen-Wah
Original Assignee
Amgen Inc
Medimmune Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc, Medimmune Llc filed Critical Amgen Inc
Publication of BR112018005175A2 publication Critical patent/BR112018005175A2/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/06—Gastro-intestinal diseases
    • G01N2800/065—Bowel diseases, e.g. Crohn, ulcerative colitis, IBS
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
BR112018005175A 2015-09-17 2016-09-16 predição de resposta clínica a antagonistas de il23 usando biomarcadores de via de il23 BR112018005175A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562220062P 2015-09-17 2015-09-17
PCT/US2016/052060 WO2017049035A1 (en) 2015-09-17 2016-09-16 Prediction of clinical response to il23-antagonists using il23 pathway biomarkers

Publications (1)

Publication Number Publication Date
BR112018005175A2 true BR112018005175A2 (pt) 2018-10-16

Family

ID=58289919

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018005175A BR112018005175A2 (pt) 2015-09-17 2016-09-16 predição de resposta clínica a antagonistas de il23 usando biomarcadores de via de il23

Country Status (13)

Country Link
US (1) US11016099B2 (cg-RX-API-DMAC7.html)
EP (1) EP3349854A4 (cg-RX-API-DMAC7.html)
JP (3) JP6909208B2 (cg-RX-API-DMAC7.html)
KR (1) KR20180063127A (cg-RX-API-DMAC7.html)
CN (2) CN116672446A (cg-RX-API-DMAC7.html)
AU (1) AU2016323579A1 (cg-RX-API-DMAC7.html)
BR (1) BR112018005175A2 (cg-RX-API-DMAC7.html)
CA (1) CA2998349A1 (cg-RX-API-DMAC7.html)
HK (1) HK1258292A1 (cg-RX-API-DMAC7.html)
IL (1) IL257969A (cg-RX-API-DMAC7.html)
MX (1) MX2018003376A (cg-RX-API-DMAC7.html)
RU (1) RU2018113694A (cg-RX-API-DMAC7.html)
WO (1) WO2017049035A1 (cg-RX-API-DMAC7.html)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3244B1 (ar) 2009-10-26 2018-03-08 Amgen Inc بروتينات ربط مستضادات il – 23 البشرية
WO2016054038A1 (en) 2014-09-29 2016-04-07 Immusant, Inc. Use of hla genetic status to assess or select treatment of celiac disease
MX2018003376A (es) 2015-09-17 2018-08-15 Amgen Inc Prediccion de la respuesta clinica a antagonistas de il23 mediante el uso de biomarcadores de la via de il23.
TW201922780A (zh) 2017-09-25 2019-06-16 美商健生生物科技公司 以抗il12/il23抗體治療狼瘡之安全且有效之方法
WO2019113037A1 (en) * 2017-12-04 2019-06-13 Immusant, Inc. Measurement of ccl20 after gluten exposure
JP7901967B2 (ja) * 2017-12-07 2026-08-07 アムジエン・インコーポレーテツド 特発性血小板減少症紫斑病(itp)をロミプロスチムで治療する方法
JP7516250B2 (ja) * 2018-03-05 2024-07-16 ヤンセン バイオテツク,インコーポレーテツド 抗il-23特異的抗体を用いたクローン病の治療方法
WO2019220412A2 (en) * 2018-05-18 2019-11-21 Janssen Biotech, Inc. Safe and effective method of treating lupus with anti-il12/il23 antibody
WO2020016838A2 (en) * 2018-07-18 2020-01-23 Janssen Biotech, Inc. Sustained response predictors after treatment with anti-il23 specific antibody
HUE063462T2 (hu) * 2018-09-24 2024-01-28 Janssen Biotech Inc A colitis ulcerosa kezelésének biztonságos és hatékony eljárása anti-IL12/IL23 antitesttel
EP3884276A2 (en) * 2018-11-23 2021-09-29 Katholieke Universiteit Leuven Predicting a treatment response in inflammatory bowel disease
CN109337974B (zh) * 2018-12-14 2022-01-25 北京蛋白质组研究中心 一种检测银屑病的诊断标志物的试剂及其应用
WO2020128864A1 (en) * 2018-12-18 2020-06-25 Janssen Biotech, Inc. Safe and effective method of treating lupus with anti-il12/il23 antibody
MX2021011328A (es) * 2019-03-18 2021-12-10 Janssen Biotech Inc Método para tratar la psoriasis en sujetos pediátricos con anticuerpo anti-il12/il23.
EP3946592A4 (en) * 2019-03-26 2023-01-04 Astrazeneca Collaboration Ventures, LLC PATIENT POPULATIONS LIKELY TO BENEFIT FROM IL23 ANTAGONIST THERAPY
US20230096620A1 (en) * 2019-04-17 2023-03-30 Millennium Pharmaceuticals, Inc. Alpha4beta7 inhibitor and il-23 inhibitor combination therapy
EP3972690A4 (en) 2019-05-23 2023-07-05 Janssen Biotech, Inc. METHOD OF TREATMENT OF INFLAMMATORY BOWEL DISEASE USING COMBINATION THERAPY OF ANTIBODIES TO IL-23 AND TNF-ALPHA
JP2022544992A (ja) * 2019-08-21 2022-10-24 アストラゼネカ・コラボレイション・ベンチャーズ・リミテッド・ライアビリティ・カンパニー クローン病を治療するためのブラジクマブの使用
EP4045085A4 (en) * 2019-10-18 2023-11-15 Janssen Biotech, Inc. SAFE AND EFFECTIVE METHOD OF TREATING ULCERATIVE COLITIS WITH ANTI-IL12/IL23 ANTIBODIES
EP4067372A4 (en) * 2019-11-29 2023-11-08 Toyobo Co., Ltd. RECOMBINANT C-REACTIVE PROTEIN
CA3164996A1 (en) * 2019-12-20 2021-06-14 Novarock Biotherapeutics, Ltd. Anti-interleukin-23 p19 antibodies and methods of use thereof
IL295545A (en) * 2020-02-14 2022-10-01 Janssen Biotech Inc Safe and effective method of treating ulcerative colitis with anti-il-12/il23 antibody
CN111424086A (zh) * 2020-03-19 2020-07-17 上海交通大学 用于胃癌诊断及预后评估的生物标记物及应用和检测试剂盒
US20230152314A1 (en) * 2020-04-10 2023-05-18 The Johns Hopkins University Lipocalin-2 assay for intestinal adaptation
CA3183927A1 (en) 2020-05-21 2021-11-25 Janssen Biotech, Inc. Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf alpha
MX2023004724A (es) * 2020-10-23 2024-02-23 Hq Han Antagonistas bifuncionales de la activina y del factor alfa de necrosis tumoral y usos de los mismos.
KR20230165746A (ko) 2020-11-30 2023-12-05 민데라 코포레이션 마이크로니들 디바이스 및 방법, 및 피부 병태 어세이
US20220373539A1 (en) * 2021-05-24 2022-11-24 Amgen Inc. Prediction of clinical response to il23-antagonists using il23 pathway biomarkers
AU2025218720A1 (en) 2024-02-06 2026-05-21 Paragon Therapeutics, Inc. Il-23 antibody compositions and methods of use
WO2025171006A1 (en) 2024-02-06 2025-08-14 Paragon Therapeutics, Inc. Il-23 binding protein compositions and methods of use

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8318754D0 (en) 1983-07-11 1983-08-10 Fagerhol M K F Human proteins anti-sera test kits
US5455160A (en) 1993-05-27 1995-10-03 Fagerhol; Magne K. Diagnostic test and kit for disease or disorders in the digestive system
DE69731103T2 (de) 1996-11-01 2005-11-17 Fagerhol, Magne K., Dr. Verfahren zur proteinextraktion
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
ZA986596B (en) 1997-07-25 1999-02-08 Schering Corp Mammalian cytokine related reagents
US7226591B2 (en) 2000-05-22 2007-06-05 Genentech, Inc. Interleukin-22 polypeptides, nucleic acids encoding the same and methods for the treatment of pancreatic disorders
DK1311679T3 (da) 2000-08-24 2009-02-23 Genentech Inc Fremgangsmåde til inhibering af IL-22-induceret PAP1
EP1756138A4 (en) 2004-03-05 2009-07-01 Archemix Corp APTAMERS FACILITATED TO THE FAMILY OF HUMAN IL-12 CYTOKINS AND THEIR USE AS THERAPEUTICS AGAINST AUTOIMMUNE DISEASES
CA2565701A1 (en) 2004-05-06 2005-11-17 Jonathan M. Barasch Ngal for reduction and amelioration of ischemic and nephrotoxic injuries
KR100681763B1 (ko) 2005-02-28 2007-02-15 재단법인 목암생명공학연구소 인간 리포칼린 2를 유효성분으로 포함하는 암 전이 억제용약학적 조성물, 이를 이용한 암 전이 억제 방법
CA2613818C (en) 2005-06-30 2013-08-27 Centocor, Inc. Anti-il-23 antibodies, compositions, methods and uses
SI1937721T1 (sl) 2005-08-25 2010-11-30 Lilly Co Eli Anti il protitelesa
ME02705B (me) 2005-08-31 2017-10-20 Merck Sharp & Dohme Inženjerisana anti-il-23 antitela
DE602006009834D1 (de) 2005-09-01 2009-11-26 Schering Corp Verwendung von il-23 und il-17-antagonisten zur behandlung von autoimmuner entzündlicher augenerkrankung
SI3219328T1 (sl) 2005-12-29 2020-10-30 Janssen Biotech, Inc. Človeška protitelesa proti-IL-23, sestavki, postopki in uporabe
US20070203216A1 (en) 2006-02-14 2007-08-30 Bjarke Ebert Method of treating inflammatory diseases
WO2007098065A2 (en) 2006-02-17 2007-08-30 The United States Of America As Represented By The Department Of Veterans Affairs Human sodium channel isoforms
JP2009540018A (ja) 2006-06-13 2009-11-19 ザイモジェネティクス, インコーポレイテッド Il−17およびil−23アンタゴニストならびにその使用方法
CN101472611A (zh) 2006-06-19 2009-07-01 惠氏公司 调节il-22和il-17的方法
GB0613470D0 (en) 2006-07-06 2006-08-16 Ares Trading Sa Protein
US7943310B2 (en) 2006-08-30 2011-05-17 Centocor Ortho Biotech Inc. Methods for assessing response to therapy in subjects having ulcerative colitis
CN103396489A (zh) 2007-02-23 2013-11-20 默沙东公司 工程改造的抗IL-23p19抗体
HUE042172T2 (hu) 2007-02-23 2019-06-28 Merck Sharp & Dohme Genetikailag elõállított anti-il-23P19 antitestek
AR068723A1 (es) 2007-10-05 2009-12-02 Glaxo Group Ltd Proteina que se une a antigenos que se une a il-23 humana y sus usos
US20090269777A1 (en) 2007-10-19 2009-10-29 Abbott Laboratories Immunoassays and kits for the detection of ngal
US20090123946A1 (en) 2007-10-19 2009-05-14 Abbott Laboratories Immunoassays and kits for the detection of ngal
EP2225268B1 (en) 2007-10-19 2012-08-29 Abbott Laboratories Immunoassays and kits for the detection of ngal
EP2215481B2 (en) 2007-11-15 2017-01-18 Bioporto Diagnostics A/S Diagnostic use of individual molecular forms of a biomarker
WO2009082624A2 (en) 2007-12-10 2009-07-02 Zymogenetics, Inc. Antagonists of il-17a, il-17f, and il-23 and methods of using the same
KR20100124326A (ko) 2008-03-14 2010-11-26 엑사젠 다이어그노스틱스, 인코포레이티드 염증성 장 질병 및 과민성 장 증후군에 대한 생체마커
US20100227775A1 (en) 2008-04-16 2010-09-09 Abbott Laboratories Immunoassays and kits for the detection of ngal
WO2010027766A1 (en) 2008-08-27 2010-03-11 Schering Corporation Lyophilized formulatons of engineered anti-il-23p19 antibodies
GB2464183A (en) 2008-09-19 2010-04-14 Singulex Inc Sandwich assay
EP2347256A4 (en) 2008-10-09 2012-02-08 Alfagene Bioscience Inc USE AND IDENTIFY BIOMARKERS FOR STOMACH DISEASES
US20100105150A1 (en) 2008-10-24 2010-04-29 Abbott Laboratories Isolated human autoantibodies to neutrophil gelatinase-associated lipocalin (ngal) and methods and kits for the detection of human autoantibodies to ngal
EP2352762A1 (en) 2008-11-03 2011-08-10 Schering Corporation Inflammatory bowel disease biomarkers and related methods of treatment
WO2010115786A1 (en) 2009-04-01 2010-10-14 Glaxo Group Limited Anti-il-23 immunoglobulins
WO2010129964A1 (en) 2009-05-08 2010-11-11 The Board Of Trustees Of The University Of Illinois Drug targets for prevention of arrhythmia in heart disease
WO2010142534A1 (en) 2009-05-27 2010-12-16 Ablynx Nv Biparatopic protein constructs directed against il-23
ES2509616T3 (es) 2009-06-25 2014-10-17 Nestec S.A. Procedimientos de diagnóstico del síndrome del intestino irritable
EP2451969A2 (en) 2009-07-07 2012-05-16 University Of Southern California Biomarkers for the early detection of autoimmune diseases
JO3244B1 (ar) 2009-10-26 2018-03-08 Amgen Inc بروتينات ربط مستضادات il – 23 البشرية
CA2781654A1 (en) 2009-11-25 2011-06-03 Hua Gong Novel genomic biomarkers for irritable bowel syndrome diagnosis
SI2523688T1 (en) 2010-01-15 2018-03-30 Kirin-Amgen, Inc. Formulation of antibodies and therapeutic regimes
JP5972871B2 (ja) 2010-07-20 2016-08-17 テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド 抗il−23ヘテロ二量体特異的抗体
US8541180B1 (en) 2010-10-11 2013-09-24 Genova Diagnostics, Inc. Compositions and methods for assessing gastrointestinal health
KR102049223B1 (ko) * 2010-11-04 2019-11-28 베링거 인겔하임 인터내셔날 게엠베하 항-il-23 항체
JP6116485B2 (ja) 2011-01-06 2017-04-19 ザ ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ イリノイ 心臓性突然死に関連する方法において使用するためのscn5aスプライスバリアント
GB201100282D0 (en) 2011-01-07 2011-02-23 Ucb Pharma Sa Biological methods
US10208349B2 (en) 2011-01-07 2019-02-19 Ucb Biopharma Sprl Lipocalin 2 as a biomarker for IL-17 inhibitor therapy efficacy
JP2014507160A (ja) 2011-02-22 2014-03-27 カリス ライフ サイエンシズ ルクセンブルク ホールディングス エス.アー.エール.エル. 循環バイオマーカー
EP3825693A1 (en) 2011-04-29 2021-05-26 Cancer Prevention And Cure, Ltd. Methods of identification and diagnosis of lung diseases using classification systems and kits thereof
EP2710383B1 (en) 2011-05-16 2017-01-11 The University of Newcastle Performance of a biomarker panel for irritable bowel syndrome
NO336551B1 (no) 2011-06-21 2015-09-28 Magne Fagerhol Forbedret ELISA for kalprotektin i fekalprøve eller gastrointestinaltraktsprøve
NO20110895A1 (no) 2011-06-21 2012-12-24 Magne Fagerhol Kompetitive S100A9 immunoanalyser
CN103874770A (zh) 2011-08-08 2014-06-18 卡里斯生命科学卢森堡控股有限责任公司 生物标志物组合物和方法
WO2013116657A1 (en) * 2012-02-03 2013-08-08 Teva Pharmaceutical Industries Ltd. USE OF LAQUINIMOD FOR TREATING CROHN'S DISEASE PATIENTS WHO FAILED FIRST-LINE ANTI-TNFα THERAPY
WO2013132338A2 (en) 2012-03-06 2013-09-12 Calpro As Competitive immunoassay for calprotectin
WO2013132347A2 (en) 2012-03-06 2013-09-12 Calpro As Improved elisa immunoassay for calprotectin
WO2013152114A1 (en) 2012-04-03 2013-10-10 The Regents Of The University Of Michigan Biomarker associated with irritable bowel syndrome and crohn's disease
KR101850591B1 (ko) * 2012-10-05 2018-04-19 제넨테크, 인크. 염증성 장 질환의 진단 및 치료 방법
KR102757668B1 (ko) 2014-05-15 2025-01-21 메소 스케일 테크놀러지즈, 엘엘시 개선된 분석 방법
WO2015191783A2 (en) 2014-06-10 2015-12-17 Abbvie Inc. Biomarkers for inflammatory disease and methods of using same
EP3172339A1 (en) * 2014-07-24 2017-05-31 Boehringer Ingelheim International GmbH Biomarkers useful in the treatment of il-23a related diseases
MX2018003376A (es) 2015-09-17 2018-08-15 Amgen Inc Prediccion de la respuesta clinica a antagonistas de il23 mediante el uso de biomarcadores de la via de il23.
GB201521357D0 (en) 2015-12-03 2016-01-20 Univ Liverpool Methods for predicting response to anti-TNF therapy
WO2017112536A1 (en) 2015-12-22 2017-06-29 Amgen Inc. Ccl20 as a predictor of clinical response to il23-antagonists
US20200064357A1 (en) 2016-11-09 2020-02-27 Protagonist Therapeutics, Inc. Methods for determining and monitoring gastrointestinal inflammation
WO2018119626A1 (zh) 2016-12-27 2018-07-05 菲鹏生物股份有限公司 中性粒细胞明胶酶相关脂质运载蛋白检测试剂盒

Also Published As

Publication number Publication date
WO2017049035A1 (en) 2017-03-23
HK1258292A1 (zh) 2019-11-08
AU2016323579A1 (en) 2018-04-05
EP3349854A4 (en) 2019-04-03
CA2998349A1 (en) 2017-03-23
JP2023002583A (ja) 2023-01-10
RU2018113694A3 (cg-RX-API-DMAC7.html) 2020-01-31
JP2018535394A (ja) 2018-11-29
US20180252728A1 (en) 2018-09-06
IL257969A (en) 2018-05-31
CN116672446A (zh) 2023-09-01
CN108290058B (zh) 2023-05-16
JP2021170017A (ja) 2021-10-28
EP3349854A1 (en) 2018-07-25
KR20180063127A (ko) 2018-06-11
RU2018113694A (ru) 2019-10-17
MX2018003376A (es) 2018-08-15
JP7153775B2 (ja) 2022-10-14
CN108290058A (zh) 2018-07-17
JP6909208B2 (ja) 2021-07-28
US11016099B2 (en) 2021-05-25

Similar Documents

Publication Publication Date Title
IL257969A (en) Predicting clinical response to interleukin-23 antagonists using interleukin-23 pathway markers
EP2906114A4 (en) FORECASTING THE RESPONSE TO STIMULI
IL254608A0 (en) Techniques for automated determination of form responses
IL250221A0 (en) Biomarkers for predicting response of dlbcl to treatment with a btk inhibitor
IL245962A0 (en) Measurement of multiple patterning parameters
EP2981522A4 (en) PPAR AGONISTS
EP3323070A4 (en) Neo-antigen-ANALYSIS
IL255029A0 (en) Predicting response to alvocidib by mitochondrial profiling
DK3049979T3 (da) Struktur-baseret prædiktiv konstruktion
HRP20181871T1 (hr) Diesteri acikličkih nukleozidnih fosfonata
DK3283499T3 (da) Dual quencher probes
EP3333331A4 (en) BUILDING STRUCTURE FOR MODULAR CONTAINERHAUS
EP3105710C0 (en) COORDINATE ANALYSIS OF PERIODIC DATA DELAY
PL3971212T3 (pl) Białka wiążące antygen receptora onkostatyny m
LT3068800T (lt) Fcrn receptoriui specifiniai antikūnai
DK2908685T3 (da) Træningsfodtøj
EP2722332A4 (en) CHINOLYLPYRROLOPYRIMIDYL COMPOUND WITH CONDENSED RING OR SALT THEREOF
EP3373918A4 (en) PREPARATION OF CARBOXYLATED NANOCELLULOSES
HRP20181560T1 (hr) H3 antagonisti sadržeći fenoksipiperdinsku jezgrenu strukturu
EP3338088A4 (en) BIOMARKER FOR CORONARY DISEASE
DK3207052T3 (da) Biosensor baseret på gbetagamma-interagerende proteiner til at monitorere g-proteinaktivering
EP3364876C0 (en) DISPOSABLE MEASURING TOOL
IL251947A0 (en) Predicting response to a vegf antagonist
FI20155387A7 (fi) Sterolien tuottaminen
EP3865472C0 (en) THROMBOXANE RECEPTOR ANTAGONISTS

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B04C Request for examination: application reinstated [chapter 4.3 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements